专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

WO2005075635A3 COAGULATION FACTOR VII/VIIA VARIANTS LACKING A FUNCTIONAL LIPID MEMBRANE BINDING DOMAIN 审中-公开
标题翻译：凝血因子VII / VIIA缺失功能性脂蛋白结合域的变异体
公开(公告)号：WO2005075635A3
公开(公告)日：2005-10-06
申请号：PCT/EP2005050474
申请日：2005-02-03
申请人： NOVO NORDISK HEALTHCARE AG , OESTERGAARD HENRIK , PERSSON EGON
发明人： OESTERGAARD HENRIK , PERSSON EGON
IPC分类号： A61K38/48 , C12N9/64
CPC分类号： A61K38/4846 , C12N9/6437 , C12N9/647 , C12Y304/21021
摘要： The present invention relates to novel coagulation factor FVIIa polypeptides.
摘要翻译：本发明涉及新型凝血因子FVIIa多肽。

62. 发明申请

WO0075279A3 NUCLEOTIDE SEQUENCES FOR GENE REGULATION AND METHODS OF USE THEREOF 审中-公开
标题翻译：用于基因调控的核苷酸序列及其使用方法
公开(公告)号：WO0075279A3
公开(公告)日：2005-09-22
申请号：PCT/US0015728
申请日：2000-06-06
申请人： UNIV MICHIGAN , KURACHI KOTOKU , KURACHI SUMIKO
发明人： KURACHI KOTOKU , KURACHI SUMIKO
IPC分类号： C12N15/09 , A61K31/7088 , A61K38/00 , A61K39/395 , A61K48/00 , A61P1/16 , A61P3/10 , A61P7/02 , A61P9/10 , A61P19/02 , A61P19/10 , A61P25/16 , A61P25/28 , A61P35/00 , C07K14/47 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/64 , C12N1/00
CPC分类号： C12N9/644 , A01K2217/05 , C07K14/4702 , C12N9/647 , C12Y304/21022
摘要： The invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest. In particular, the invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest in an age-related manner and/or in a liver-specific manner. The invention further provides methods of using the regulatory nucleic acid sequences provided herein for age-related and/or liver-specific expression of nucleotides sequences of interest. The invention also provides host cells and transgenic non-human animals which harbor the regulatory nucleic acid sequences of the invention. The compositions and methods of the invention are useful in regulating expression of a nucleotide sequence of interest in an age-related and/or liver-specific manner.
摘要翻译：本发明提供调节目的核苷酸序列表达的核酸序列。特别地，本发明提供了以年龄相关的方式和/或肝脏特异性方式调节感兴趣的核苷酸序列的表达的核酸序列。本发明进一步提供使用本文提供的调节性核酸序列用于感兴趣的核苷酸序列的年龄相关和/或肝特异性表达的方法。本发明还提供含有本发明的调节性核酸序列的宿主细胞和转基因非人动物。本发明的组合物和方法可用于调节年龄相关和/或肝特异性方式的感兴趣的核苷酸序列的表达。

63. 发明申请

WO2005075635A2 NOVEL COMPOUNDS 审中-公开
标题翻译：新型化合物
公开(公告)号：WO2005075635A2
公开(公告)日：2005-08-18
申请号：PCT/EP2005/050474
申请日：2005-02-03
申请人： NOVO NORDISK HEALTH CARE AG , ØSTERGAARD, Henrik , PERSSON, Egon
发明人： ØSTERGAARD, Henrik , PERSSON, Egon
IPC分类号： C12N9/64
CPC分类号： A61K38/4846 , C12N9/6437 , C12N9/647 , C12Y304/21021 , Y02A50/473 , Y02A50/481
摘要： The present invention relates to novel coagulation factor FVIIa polypeptides.
摘要翻译：本发明涉及新型凝血因子FVIIa多肽。

64. 发明申请

WO2004069207A2 IMMUNOGENIC CD91 LIGAND-ANTIGENIC MOLECULE COMPLEXES AND FUSION PROTEINS 审中-公开
标题翻译：免疫原性CD91配体 - 抗原分子复合物和融合蛋白
公开(公告)号：WO2004069207A2
公开(公告)日：2004-08-19
申请号：PCT/US2004/003865
申请日：2004-02-04
申请人： UNIVERSITY OF CONNECTICUT HEALTH CENTER , SRIVASTAVA, Pramod, K.
发明人： SRIVASTAVA, Pramod, K.
IPC分类号： A61K
CPC分类号： C12N9/647 , A61K39/00 , A61K39/39 , A61K2039/60 , A61K2039/6031 , C07K14/78 , C07K14/8114 , C07K14/8121 , C07K14/8128 , C07K2319/00 , C12N9/20 , C12N9/6491
摘要： The present invention relates to complexes and fusion proteins comprising a CD91 ligand and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides complexes comprising a CD91 ligand noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The invention also specifically provides fusion proteins comprising a CD91 ligand fused via a peptide bond to an antigenic molecule.
摘要翻译：本发明涉及包含CD91配体和抗原性分子的复合物和融合蛋白，用于治疗或预防疾病。本发明特别提供了包含与抗原性分子非共价结合或交联的CD91配体的复合物。本发明还特别提供了包含通过肽键与抗原分子融合的CD91配体的融合蛋白。

65. 发明申请

WO0222776A9 HUMAN COAGULATION FACTOR VII VARIANTS 审中-公开
标题翻译：人类凝血因子VII变种
公开(公告)号：WO0222776A9
公开(公告)日：2003-05-22
申请号：PCT/DK0100596
申请日：2001-09-13
申请人： NOVO NORDISK AS , PERSSON EGON , OLSEN OLE HVILSTED
发明人： PERSSON EGON , OLSEN OLE HVILSTED
IPC分类号： A01H5/00 , A01H1/00 , A01K67/00 , A01K67/027 , A61K38/00 , A61K38/36 , A61K38/48 , A61P7/04 , A61P41/00 , C07K20060101 , C07K14/745 , C12N20060101 , C12N5/10 , C12N9/64 , C12N15/09 , C12N15/12 , C12P21/02
CPC分类号： C12N9/647 , A61K38/4846 , C12N9/6437 , C12Y304/21021
摘要： The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment. The variant comprises a substitution in at least one amino acid position, selected from the group consisting of positions Lys 157, Lys 337, Asp 334, Ser 336, Val 158, Glu 296 and Met 298.
摘要翻译：本发明涉及具有凝血活性的新型人凝血因子VIIa变体以及编码这样的变体，载体和宿主细胞的核酸构建体，其包含并表达核酸，药物组合物，用途和治疗方法。该变体包含至少一个选自Lys 157，Lys 337，Asp 334，Ser 336，Val 158，Glu 296和Met 298的氨基酸位置的取代。

66. 发明申请

WO0240544A2 MUTANT HUMAN FACTOR IX WITH AN INCREASED RESISTANCE TO INHIBITION BY HEPARIN 审中-公开
标题翻译：突变型人因子IX具有耐药性，可以抑制HEPARIN
公开(公告)号：WO0240544A2
公开(公告)日：2002-05-23
申请号：PCT/US0147276
申请日：2001-11-13
申请人： UNIV TEXAS SYSTEMS , SHEEHAN JOHN P
发明人： SHEEHAN JOHN P
IPC分类号： C07K14/745 , C12N9/64 , C12N15/57
CPC分类号： C12N9/647 , C07K14/745 , C12N9/644 , C12Y304/21022 , Y10S514/802
摘要： The present invention is related to a novel composition of matter and methods of using the same. More particularly, the invention describes mutant human factor IX which has an increased resistance to inhibition by heparin. Methods of making and using this composition for the therapeutic intervention of hemophilia are disclosed.
摘要翻译：本发明涉及一种新颖的物质组合物及其使用方法。更具体地，本发明描述了具有增加的对肝素抑制的抗性的突变体人因子IX。公开了制备和使用该组合物用于血友病治疗干预的方法。

67. 发明申请

WO0222776A2 HUMAN COAGULATION FACTOR VII VARIANTS 审中-公开
标题翻译：人类凝血因子VII变种
公开(公告)号：WO0222776A2
公开(公告)日：2002-03-21
申请号：PCT/DK0100596
申请日：2001-09-13
申请人： NOVO NORDISK AS , PERSSON EGON , OLSEN OLE HVILSTED
发明人： PERSSON EGON , OLSEN OLE HVILSTED
IPC分类号： A01H5/00 , A01H1/00 , A01K67/00 , A01K67/027 , A61K38/00 , A61K38/36 , A61K38/48 , A61P7/04 , A61P41/00 , C07K20060101 , C07K14/745 , C12N20060101 , C12N5/10 , C12N9/64 , C12N15/09 , C12N15/12 , C12P21/02 , C12N
CPC分类号： C12N9/647 , A61K38/4846 , C12N9/6437 , C12Y304/21021
摘要： The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment.
摘要翻译：本发明涉及具有凝血活性的新型人凝血因子VIIa变体以及编码这样的变体，载体和宿主细胞的核酸构建体，其包含并表达核酸，药物组合物，用途和治疗方法。

68. 发明申请

WO00075279A2 NUCLEOTIDE SEQUENCES FOR GENE REGULATION AND METHODS OF USE THEREOF 审中-公开
标题翻译：用于基因调控的核苷酸序列及其使用方法
公开(公告)号：WO00075279A2
公开(公告)日：2000-12-14
申请号：PCT/US2000/015728
申请日：2000-06-06
IPC分类号： C12N15/09 , A61K31/7088 , A61K38/00 , A61K39/395 , A61K48/00 , A61P1/16 , A61P3/10 , A61P7/02 , A61P9/10 , A61P19/02 , A61P19/10 , A61P25/16 , A61P25/28 , A61P35/00 , C07K14/47 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/64 , C12N
CPC分类号： C12N9/644 , A01K2217/05 , C07K14/4702 , C12N9/647 , C12Y304/21022
摘要： The invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest. In particular, the invention provides nucleic acid sequences which regulate expression of a nucleotide sequence of interest in an age-related manner and/or in a liver-specific manner. The invention further provides methods of using the regulatory nucleic acid sequences provided herein for age-related and/or liver-specific expression of nucleotides sequences of interest. The invention also provides host cells and transgenic non-human animals which harbor the regulatory nucleic acid sequences of the invention. The compositions and methods of the invention are useful in regulating expression of a nucleotide sequence of interest in an age-related and/or liver-specific manner.
摘要翻译：本发明提供调节目的核苷酸序列表达的核酸序列。特别地，本发明提供了以年龄相关的方式和/或肝特异性方式调节目的核苷酸序列的表达的核酸序列。本发明进一步提供使用本文提供的调节性核酸序列用于感兴趣的核苷酸序列的年龄相关和/或肝特异性表达的方法。本发明还提供了携带本发明的调节性核酸序列的宿主细胞和转基因非人动物。本发明的组合物和方法可用于调节年龄相关和/或肝特异性方式的感兴趣的核苷酸序列的表达。

69. 发明申请

WO1992001795A1 GAMMA-CARBOXYLASE AND METHODS OF USE 审中-公开
标题翻译： γ-羟基羧酸酶及其使用方法
公开(公告)号：WO1992001795A1
公开(公告)日：1992-02-06
申请号：PCT/US1991005177
申请日：1991-07-22
申请人： ZYMOGENETICS, INC.
发明人： ZYMOGENETICS, INC. , BERKNER, Kathleen, L.
IPC分类号： C12N15/60
CPC分类号： C12N9/647 , C12N9/88 , F02B2075/027
摘要： Protein compositions having gamma-carboxylase activity enriched at least 20,000-fold as compared to liver microsomes are provided. Also provided are DNA molecules encoding gamma-carboxylase. The protein compositions and DNA molecules are useful within methods of producing gamma-carboxylated vitamin K-dependent proteins.
摘要翻译：提供了具有与肝微粒体相比富含至少20,000倍的γ-羧化酶活性的蛋白质组合物。还提供了编码γ-羧化酶的DNA分子。蛋白质组合物和DNA分子可用于产生γ-羧化维生素K依赖性蛋白质的方法。

70. 发明申请

WO1991001138A1 SEQUENTIAL HEAT TREATMENT OF BLOOD-CLOTTING FACTOR PRODUCTS 审中-公开
标题翻译：血液粘稠因子产品的顺序热处理
公开(公告)号：WO1991001138A1
公开(公告)日：1991-02-07
申请号：PCT/US1990001088
申请日：1990-02-26
申请人： INTERNATIONAL MEDICAL TECHNOLOGIES CORP.
发明人： INTERNATIONAL MEDICAL TECHNOLOGIES CORP. , RUBINSTEIN, Alan, I.
IPC分类号： A61K35/14
CPC分类号： C12N9/647 , A61K38/00 , A61L2/0023 , C07K14/75 , C07K14/755
摘要： Factor VIII concentrate, or Factor IX concentrate, or fibrinogen concentrate, or other clotting-factor product, is subjected to a sequence of heating steps to reduce the infectivity of a virus (such as hepatitis - or AIDS-causing virus), if present. The heating is performed while the concentrate is lyophilized (or dried by another process). The heating steps in the sequence are for two or more different times, and at two or more different temperatures. After the heating sequence, the concentrate is reconstitued for use. This sequential method contemplates greater inactivation of different viral forms, or reduction of the heating required, or both. Reduction of heating requirements may appear as reduced overall heating time, or reduced aggregate power consumption, or both. Advantages include heightened quality-control assurance level. Also possibly, the invention offers some potential for preparation of vaccines against the virus, if sufficient quantity of the virus is present in the concentrate.
摘要翻译：将因子VIII浓缩物或因子IX浓缩物或纤维蛋白原浓缩物或其它凝血因子产物经受一系列加热步骤以降低病毒（例如导致肝炎或致艾滋病毒的病毒）的感染性（如果存在）。在将浓缩物冻干（或通过另一方法干燥）的同时进行加热。序列中的加热步骤为两个或更多个不同的时间，并且在两个或更多个不同的温度下。在加热顺序之后，浓缩物重新配制使用。这种顺序方法考虑到不同病毒形式的更大失活，或所需加热的减少，或两者兼而有之。加热要求的降低可能出现在总体加热时间减少或总体功耗降低或两者之间。优势包括提高质量控制保证水平。还有可能的是，如果浓缩物中存在足够数量的病毒，本发明提供了一些制备抗病毒疫苗的潜力。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式